{"groups":[{"description":"Beginning on day 3 after auto Hematopoietic Cell Transplantation (HSCT), patients receive tbo-filgrastim SC daily for 12-14 days.\n\nHematopoietic Cell Transplantation: Undergo auto HSCT\n\nTbo-filgrastim: Given subcutaneously\n\nLaboratory Biomarker Analysis: Correlative Studies","id":"FG000","title":"Group I (auto HSCT tbo-filgrastim)"},{"description":"Patients undergo auto Hematopoietic Cell Transplantation (HSCT).\n\nHematopoietic Cell Transplantation: Undergo auto HSCT\n\nLaboratory Biomarker Analysis: Correlative Studies","id":"FG001","title":"Group II (auto HSCT)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"9"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"38"},{"groupId":"FG001","numSubjects":"39"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"32"},{"groupId":"FG001","numSubjects":"30"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"9"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}